Protocol for the SACLA trial: Efficacy and safety of subretinal monteplase for submacular hemorrhage in a phase II single-arm multicenter decentralized clinical trial
PLOS One · 02.07.2026 · 21 (7) · e0353127
DOI: 10.1371/journal.pone.0353127 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PLOS One, online erschienen am 02.07.2026. Verfasst von Noriko Yoshida und 24 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Saga University Hospital, Saga, Japan. Hauptthemen laut MEDLINE: Retinal Hemorrhage, Tissue Plasminogen Activator, Fibrinolytic Agents. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japanese Agency for Medical Research and Development.
Abstract (Originalsprache)
Submacular hemorrhage (SMH), which may arise from age-related macular degeneration, retinal arterial macroaneurysm, and other causes, can result in severe vision loss and central visual field impairment. Although tissue plasminogen activator (tPA) is used off-label to treat SMH in many countries, no formulation has been approved for this indication. Because early intervention is critical when tPA is used for SMH, limited access to centers that can provide this treatment may delay care and reduce treatment opportunities. Decentralized clinical trials (DCTs) reduce or eliminate the need for participants to travel to trial sites. We therefore designed the investigator-initiated SACLA trial to evaluate subretinal tPA for SMH. The DCT framework is intended to reduce logistical barriers related to the disease severity and rarity. The SACLA trial is a phase II multicenter, open-label, single-arm surgical study with a pre-post comparison design (jRCT2071250003). Twenty eligible participants will undergo pars plana vitrectomy followed by subretinal injection of 0.1 mL (8,000 IU) of tPA. Participants will remain hospitalized at the trial site until the primary outcome, change in central foveal thickness (CFT) from baseline at Week 1, is assessed. Thereafter, follow-up visits will be conducted at either the trial site or partner sites within the DCT framework. Secondary efficacy outcomes include change in CFT from baseline, presence of a foveal hemorrhage measuring at least 1 disc diameter, best-corrected visual acuity (BCVA), and change in BCVA from baseline at Weeks 4 and 12. Adverse events will be collected throughout the 12-week observation period to assess safety. The protocol and related study documents were reviewed and approved by the Saga University Hospital Institutional Review Board. This study is designed to generate prospective evidence on the feasibility, short-term anatomical response, and safety of subretinal tPA for SMH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Research Center, Saga University Hospital, Saga, Japan.
- Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
- Department of Pharmacy, Saga University Hospital, Saga, Japan.
- Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga, Japan.
- Education and Research Centre for Community Medicine, Faculty of Medicine, Saga University, Saga, Japan.
- Department of Medical Technology and Science, Faculty of Fukuoka Health Care, International University of Health and Welfare, Fukuoka, Japan.
ORCID-Profile: Noriko Yoshida, Takuma Furukawa, Toshihiro Inoue, Atsunobu Takeda, Makoto Inoue
Förderung
- Japanese Agency for Medical Research and Development
Zitieren
APA
Yoshida, N., Kobayakawa, Y., Funakoshi, K., Kimura, S., Hosoya, K., Shinkawa, Y., Furukawa, T., Mitsutake, T., Hoshiko, T., Takamori, A., Kawahara, N., Terasaki, H., Oishi, A., Koizumi, H., Inoue, T., Takeda, A., Ikeda, Y., Yoshida, S., Morizane, Y., …, & Enaida, H. (2026). Protocol for the SACLA trial: Efficacy and safety of subretinal monteplase for submacular hemorrhage in a phase II single-arm multicenter decentralized clinical trial. PLOS One, 21(7), e0353127. https://doi.org/10.1371/journal.pone.0353127
Vancouver
Yoshida N, Kobayakawa Y, Funakoshi K, Kimura S, Hosoya K, Shinkawa Y, et al. Protocol for the SACLA trial: Efficacy and safety of subretinal monteplase for submacular hemorrhage in a phase II single-arm multicenter decentralized clinical trial. PLOS One. 2026;21(7):e0353127. doi:10.1371/journal.pone.0353127
BibTeX
@article{Yoshida2026,
author = {Yoshida, Noriko and Kobayakawa, Yuko and Funakoshi, Kouta and Kimura, Sakiko and Hosoya, Kazuhisa and Shinkawa, Yuya and Furukawa, Takuma and Mitsutake, Tsubasa and Hoshiko, Toshimi and Takamori, Ayako and Kawahara, Naoto and Terasaki, Hiroto and Oishi, Akio and Koizumi, Hideki and Inoue, Toshihiro and Takeda, Atsunobu and Ikeda, Yasuhiro and Yoshida, Shigeo and Morizane, Yuki and Kadonosono, Kazuaki and Inoue, Makoto and Kamei, Motohiro and Todaka, Koji and Sonoda, Koh-Hei and Enaida, Hiroshi},
title = {Protocol for the SACLA trial: Efficacy and safety of subretinal monteplase for submacular hemorrhage in a phase II single-arm multicenter decentralized clinical trial},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0353127},
doi = {10.1371/journal.pone.0353127}
}
EUVIMED